Development and Validation of a Microdissection Method to Advance Precision Medicine in the Clinical Setting

 描述(由申请人提供)：精确医学可以通过在正确的时间为正确的患者识别正确的药物来影响癌症的治疗。然而，目前的前端病理学工具不足以满足当今复杂的功能基因组测试。为了改善患者的预后，我们提出了一种创新的技术，表达显微切割(XMD)，它利用标准的免疫组织化学来轻松、快速地从异质组织切片中分离出纯肿瘤细胞群。在我们的提案中，我们的目标是通过评估解剖效率、特异性和重复性来在临床上验证xMD技术在常见肿瘤类型上的有效性，并为xMD过程建立标准操作程序(SOP)。我们还将评估回收的DNA、RNA和蛋白质的质量，并评估xMD对检测结果的影响。最后，我们将研究一组肺癌样本，以评估xMD的稳健性，并生成详细说明每个患者样本的分子特征的全面患者报告。

 DESCRIPTION (provided by applicant): Precision medicine can impact the treatment of cancer by identifying the right drug at the right time for the right patient. However, current fron-end pathology tools are insufficient for today's sophisticated functional genomic tests. In order t improve patient outcomes, we propose to advance an innovative technology, Expression Microdissection (xMD) that utilizes standard immunohistochemistry to easily and rapidly isolate pure tumor cell populations from heterogeneous tissue sections. In our proposal, we aim to clinically validate xMD technology on common tumor types by assessing dissection efficiency, specificity, and reproducibility, and to establish standard operating procedures (SOPs) for the xMD process. We will also evaluate the quality of the recovered DNA, RNA and protein and assess the effect of xMD on assay results. Finally, we will study a set of lung cancer specimens to evaluate the robustness of xMD and generate a comprehensive patient report detailing the molecular profile of each patient specimen.